Effects of Acute Exercise and Allopurinol Administration on Soluble Urokinase Plasminogen Activator Receptor (suPAR)

被引:11
|
作者
Sanchis-Gomar, Fabian [1 ]
Bonaguri, Chiara [2 ]
Pareja-Galeano, Helios [1 ]
Carmen Gomez-Cabrera, Mari [1 ]
Candel, Jorge [3 ]
Vina, Jose [1 ]
Lippi, Giuseppe [2 ]
机构
[1] Univ Valencia, Fdn Invest Hosp Clin Univ, Fac Med, Dept Physiol,INCLIVA, Valencia 46010, Spain
[2] Univ Parma, Azienda Osped, UO Diagnost Ematochim, Dipartimento Patol & Med Lab, I-43100 Parma, Italy
[3] Valencia CF Med Serv, Valencia, Spain
关键词
physical exercise; soluble urokinase plasminogen activator receptor; suPAR; allopurinol; EXHAUSTIVE PHYSICAL-EXERCISE; MORTALITY; TOUR;
D O I
10.7754/Clin.Lab.2012.120728
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Although physical exercise acutely increases the most widely used inflammatory biomarkers, there is no information on its effect on soluble urokinase plasminogen activating receptor (suPAR), a circulating biomarker increasingly used for the assessment of systemic inflammation. Methods: suPAR was assessed with the quantitative suPARnostic (R) Standard ELISA Assay (Virogates, Birkerod, Denmark) in 12 professional football players before and after a football match. The athletes were divided into two experimental groups. An oral dose of 300 mg of allopurinol was administered to one group of six participants four hours before a match; the other six participants received placebo. Results: Serum suPAR concentration did not vary significantly after the match in both the placebo and allopurinol group. No significant differences were observed between placebo and allopurinol groups at baseline and after the game. Conclusions: At variance with other consolidated inflammatory biomarkers, suPAR is not influenced by either physical exercise or administration of xanthine oxidase inhibitors.
引用
收藏
页码:207 / 210
页数:4
相关论文
共 50 条
  • [41] Soluble urokinase Plasminogen Activator Receptor (suPAR) serum levels are elevated in patients with neuroendocrine neoplasia
    Burcin, Oe
    Mohr, R.
    Jann, H.
    Geisler, L.
    Tacke, F.
    Wiedenmann, B.
    Roderburg, C.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 96 - 96
  • [42] Soluble urokinase plasminogen activator receptor (suPAR) for the prediction of ventilator-associated pneumonia (VAP)
    van Oort, Pouline M. P.
    Bos, Lieuwe D.
    Povoa, Pedro
    Ramirez, Paula
    Torres, Antonio
    Artigas, Antonio
    Schultz, Marcus J.
    Martin-Loeches, Ignacio
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [43] Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococcus aureus bacteremia
    Molkanen, T.
    Ruotsalainen, E.
    Thorball, C. W.
    Jarvinen, A.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2011, 30 (11) : 1417 - 1424
  • [44] Analytical, biochemical and clearance considerations of soluble urokinase plasminogen activator receptor (suPAR) in healthy individuals
    Chew-Harris, Janice
    Appleby, Sarah
    Richards, A. Mark
    Troughton, Richard W.
    Pemberton, Christopher J.
    CLINICAL BIOCHEMISTRY, 2019, 69 : 36 - 44
  • [45] Soluble Urokinase Plasminogen Activator Receptor (suPAR) as an Added Predictor to Existing Preoperative Risk Assessments
    Morten Alstrup
    Jeppe Meyer
    Martin Schultz
    Line Jee Hartmann Rasmussen
    Lars Simon Rasmussen
    Lars Køber
    Jakob Lundager Forberg
    Jesper Eugen-Olsen
    Kasper Iversen
    World Journal of Surgery, 2019, 43 : 780 - 790
  • [46] Soluble urokinase-type plasminogen activator receptor (SuPAR) in patients with Parkinson's disease
    Witek, N.
    Joyce, J.
    Hawkins, J.
    Liu, Y.
    Ouyang, B.
    Patel, R.
    Borgia, J.
    Reiser, J.
    Hall, D.
    MOVEMENT DISORDERS, 2021, 36 : S460 - S460
  • [47] Soluble urokinase plasminogen activator receptor (SuPAR) in patients with plasma cell dyscrasias, a pilot study
    Sudhini, Yashwanth
    Dhakal, Binod
    Reiser, Jochen
    Altintas, Mehmet
    Hahm, Eunsil
    Peev, Vasil
    Venugopal, Parameswaran
    Paner, Agne
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S283 - S284
  • [48] Soluble urokinase-type plasminogen activator receptor (suPAR) - a possible biomarker for bacteremia in sepsis
    Georgescu, Anca-Meda
    Szederjesi, Janos
    Voidazan, Septimiu
    Dobreanu, Minodora
    Copotoiu, Sanda Maria
    Hutanu, Adina
    Azamfirei, Leonard
    REVISTA ROMANA DE MEDICINA DE LABORATOR, 2015, 23 (01): : 59 - 73
  • [49] Soluble Urokinase Plasminogen Activator Receptor (suPAR) as an Added Predictor to Existing Preoperative Risk Assessments
    Alstrup, Morten
    Meyer, Jeppe
    Schultz, Martin
    Rasmussen, Line Jee Hartmann
    Rasmussen, Lars Simon
    Kober, Lars
    Forberg, Jakob Lundager
    Eugen-Olsen, Jesper
    Iversen, Kasper
    WORLD JOURNAL OF SURGERY, 2019, 43 (03) : 780 - 790
  • [50] Serum soluble urokinase-type plasminogen activator receptor (suPAR) levels in male patients with acute exacerbation of schizophrenia
    Genc, A.
    Kalelioglu, T.
    Karamustafalioglu, N.
    Tasdemir, A.
    Genc, E. Sena
    Akkus, M.
    Emul, M. H.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 : S232 - S233